...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: My hope is

There in a BO period given the limited information/detail provided at the AGM + the weak/shallow response given today.

can't see a company like Cenora with all their resources etc taking long to do their DD - expecting another NR within 30 to 45 days max. Just can't believe there's nothing significant going on behind the scenes. I'll pipe down for the above period in hopes I'm correct this time - it will be the first time... sigh 

Share
New Message
Please login to post a reply